Literature DB >> 19345034

Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem.

Scott A Weisenberg1, Daniel J Morgan, Rosanny Espinal-Witter, Davise H Larone.   

Abstract

Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae may appear susceptible to imipenem or meropenem by routine susceptibility testing. We report a series of patients with infections caused by K. pneumoniae isolates, which yielded imipenem-susceptible results but were subsequently KPC-positive by polymerase chain reaction. When these infections were treated with imipenem or meropenem, frequent clinical and microbiologic failures were observed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19345034      PMCID： PMC2764245          DOI： 10.1016/j.diagmicrobio.2009.02.004

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  11 in total

1.  Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.

Authors:  Neil Woodford; Philip M Tierno; Katherine Young; Luke Tysall; Marie-France I Palepou; Elaina Ward; Ronald E Painter; Deborah F Suber; Daniel Shungu; Lynn L Silver; Kenneth Inglima; John Kornblum; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

3.  Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005).

Authors:  Lalitagauri M Deshpande; Paul R Rhomberg; Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2006-10-03       Impact factor: 2.803

4.  Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.

Authors:  H Yigit; A M Queenan; G J Anderson; A Domenech-Sanchez; J W Biddle; C D Steward; S Alberti; K Bush; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Authors:  Simona Bratu; David Landman; Robin Haag; Rose Recco; Antonella Eramo; Maqsood Alam; John Quale
Journal:  Arch Intern Med       Date:  2005-06-27

6.  Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY.

Authors:  David Landman; Simona Bratu; Sandeep Kochar; Monica Panwar; Manoj Trehan; Mehmet Doymaz; John Quale
Journal:  J Antimicrob Chemother       Date:  2007-05-09       Impact factor: 5.790

7.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.

Authors:  Patricia A Bradford; Simona Bratu; Carl Urban; Melissa Visalli; Noriel Mariano; David Landman; James J Rahal; Steven Brooks; Sanda Cebular; John Quale
Journal:  Clin Infect Dis       Date:  2004-06-14       Impact factor: 9.079

8.  Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.

Authors:  Daniel J Wolter; Philip M Kurpiel; Neil Woodford; Marie-France I Palepou; Richard V Goering; Nancy D Hanson
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

9.  Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae.

Authors:  K F Anderson; D R Lonsway; J K Rasheed; J Biddle; B Jensen; L K McDougal; R B Carey; A Thompson; S Stocker; B Limbago; J B Patel
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

10.  Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.

Authors:  Samir G Sakka; Anna K Glauner; Jürgen B Bulitta; Martina Kinzig-Schippers; Wolfgang Pfister; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191
View more
  42 in total

1.  High frequency of IMP-6 among clinical isolates of metallo-β-lactamase-producing Escherichia coli in Japan.

Authors:  Hisakazu Yano; Miho Ogawa; Shiro Endo; Risako Kakuta; Hajime Kanamori; Shinya Inomata; Noriomi Ishibashi; Tetsuji Aoyagi; Masumitsu Hatta; Yoshiaki Gu; Mitsuhiro Yamada; Koichi Tokuda; Hiroyuki Kunishima; Miho Kitagawa; Yoichi Hirakata; Mitsuo Kaku
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification.

Authors:  John S Esterly; Jamie Wagner; Milena M McLaughlin; Michael J Postelnick; Chao Qi; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

3.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

Review 5.  Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues.

Authors:  Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

6.  KPC screening by updated BD Phoenix and Vitek 2 automated systems.

Authors:  Kenneth S Thomson; Iraida E Robledo; Guillermo J Vázquez; Ellen S Moland
Journal:  J Clin Microbiol       Date:  2011-07-06       Impact factor: 5.948

7.  Efficient Detection of Carbapenemase Activity in Enterobacteriaceae by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Less Than 30 Minutes.

Authors:  Camille Lasserre; Luc De Saint Martin; Gaelle Cuzon; Pierre Bogaerts; Estelle Lamar; Youri Glupczynski; Thierry Naas; Didier Tandé
Journal:  J Clin Microbiol       Date:  2015-04-29       Impact factor: 5.948

Review 8.  Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.

Authors:  E Torres; M Delgado; A Valiente; Á Pascual; J Rodríguez-Baño
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-02       Impact factor: 3.267

Review 9.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

10.  Management of infections due to KPC-producing Klebsiella pneumoniae.

Authors:  Stanley C Deresinski; Patricia Schirmer
Journal:  F1000 Med Rep       Date:  2009-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.